Jerry R. Colca

This paper identifies BIOIO-1001 as a dual mTOR/NAD+ acting gerotherapy that reduces metabolic derangements, inflammation, and fibrosis in NASH and ALS models.

This study shows that MSDC-0160, a mitochondrial pyruvate carrier inhibitor, reduces neurodegeneration in a rat Parkinson's disease model by altering energy metabolism and neuroinflammation.

The paper tests if inhibiting the mitochondrial pyruvate carrier reduces synucleinopathy in PD models but finds no effect on Syn aggregation or neurodegeneration.